BCL2L1
- 6 trials
- 6 of 6 trials sponsored by developers of drugs on it
- Human trial1
- Animals2
- Cells2
Latest
Aging
New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463
Experiments in human cellsFisetin
Aging Cell
Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors
Experiments in human cellsSenolytics
Nature Medicine
Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice
Experiments in miceBlood and immune system
Aging Cell
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Experiments in miceSenolytics
The Lancet Oncology
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Non-randomised trial in 55 peopleSenolytics